Research articleLevodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders
References (33)
Olivopontocerebellar atrophy
J. Neurol. Sci.
(1982)- et al.
[3H]Spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
Eur. J. Pharmacol.
(1984) - et al.
Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology
Brain Res.
(1989) - et al.
Cerebral circulatory and metabolic effects of piribedil
Eur. J. Pharmacol.
(1980) - et al.
The distribution of alterations in energy metabolism in the rat brain produced by apomorphine
Brain Res.
(1982) - et al.
Loss of striatal [76Br]bromos-piperone binding sites demonstrated by positron tomography in progressive supranuclear palsy
J. Cereb. Blood Flow Metab.
(1986) - et al.
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
Ann. Neurol.
(1990) - et al.
Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography
Ann. Neurol.
(1992) - et al.
Amine mechanisms in the cerebral circulation
Pharmacol. Rev.
(1977) - et al.
Nonoxidative glucose consumption during focal physiologic neural activity
Science
(1988)
Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease
Arch. Neurol.
An investigation on dementia rating scale for the elderly
Seishin Igaku
Challenge tests to predict the dopaminergic response in untreated Parkinson's disease
Neurology
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study
J. Neurol. Neurosurg. Psychiat.
Progressive supranuclear palsy: Clinical features and response to treatment in 16 patients
Ann. Neurol.
The theory and applications of the exchange of inert gas at the lungs and tissues
Pharmacol. Rev.
Cited by (34)
Dopamine effects on frontal cortical blood flow and motor inhibition in Parkinson's disease
2019, CortexCitation Excerpt :This supplementary analysis also supports the observation that CBF findings are not being driven by technical variations due to image artifacts, for instance due to variations in labeling efficiency in the pCASL sequence from scan to scan that would manifest as a globally altered CBF measurement. Previous PET and MRI studies investigating the effects of levodopa, the most commonly used dopamine precursor therapy for PD, indicate that treatment alters rCBF in several regions: the striatum and thalamus (Kobari, Fukuuchi, Shinohara, Obara, & Nogawa, 1995), nigrostriatal pathway, occipital cortex, and inferior parietal areas (Chen, Pressman, Simuni, Parrish, & Gitelman, 2015). Both levodopa and DAA augment dopaminergic tone in PD and both appear to increase rCBF in areas associated with PD symptoms, despite the differing mechanisms of action.
Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease
2014, NeuroImage: ClinicalCitation Excerpt :It is possible that differences in NVS might be influential in differing clinical phenotypes of IPD (Lee et al., 2009), however the small sample size in this study meant that phenotype-specific differences could not be explored. LED scores differed between participants, which may confound the results as previous studies have revealed regional blood flow increases with levodopa (Hershey et al., 2003; Kobari et al., 1995). This exploratory work used MRI perfusion and structural measures to investigate NVS in IPD.
Impairment of cerebral hemodynamic response to the cold pressor test in patients with Parkinson's disease
2009, Parkinsonism and Related DisordersCitation Excerpt :All can affect blood pressure and CBFV. According to previous reports [47–49], levodopa, either oral or intravenous, will induce diffuse CBFV increases, especially in the striatum and thalamus, and cause cerebrovascular dilation in patients with PD. But, from other views, these dopaminergic drugs will reduce MAP and blunt the sympathetic response [50,51].
Intravenous levodopa administration in humans based on a two-compartment kinetic model
2007, Journal of Neuroscience MethodsDopaminergic modulation of response inhibition: An fMRI study
2004, Cognitive Brain ResearchCognitive-pharmacologic functional magnetic resonance imaging in Tourette syndrome: A pilot study
2004, Biological Psychiatry